The Future of Reimbursement: How AI Can Revolutionize Oncology Practices
May 15th 2023By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2023Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL
Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.
Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status
June 6th 2022Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.
Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL
June 4th 2022At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC
May 18th 2022Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.
Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.
Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer
The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.
Digital Health and Process Improvements Enhance Community-Based Patient Care
October 20th 2021A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.
The US Oncology Network Announces Trusted Leader Jason Hammonds as New President
October 12th 2021The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that it has appointed Jason Hammonds as its new president.
Coleman Centers the Discussion on Practice-Affirming ASCO Trials in Gynecologic Oncology
June 29th 2021Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.
The US Oncology Network Highlights Success With Oncology Care Model
June 10th 2021Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.